{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:24:41Z","timestamp":1790623481051,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1136\/annrheumdis-2012-202136","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T02:00:36Z","timestamp":1353031236000},"page":"1813-1818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist"],"prefix":"10.1016","volume":"72","author":[{"given":"Daniel H","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A","family":"Rassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindee","family":"Kuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie R","family":"Harrold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie R","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2012-202136_bib1","doi-asserted-by":"crossref","first-page":"12746","DOI":"10.1073\/pnas.97.23.12746","article-title":"Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/annrheumdis-2012-202136_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2012-202136_bib3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","article-title":"Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"27","author":"Torre-Amione","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1136\/annrheumdis-2012-202136_bib4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ Res"},{"key":"10.1136\/annrheumdis-2012-202136_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1136\/annrheumdis-2012-202136_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1136\/annrheumdis-2012-202136_bib7","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1136\/annrheumdis-2012-202136_bib8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2012-202136_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1136\/annrheumdis-2012-202136_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis","volume":"156","author":"Setoguchi","year":"2008","journal-title":"Am Heart J"},{"key":"10.1136\/annrheumdis-2012-202136_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","article-title":"Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis","volume":"44","author":"Bernatsky","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2012-202136_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202136_bib13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/pds.2196","article-title":"Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems","volume":"20","author":"Herrinton","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6 Suppl","key":"10.1136\/annrheumdis-2012-202136_bib14","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/MLR.0b013e3181d59541","article-title":"Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics","volume":"48","author":"Rassen","year":"2010","journal-title":"Med Care"},{"key":"10.1136\/annrheumdis-2012-202136_bib15","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2012-202136_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00005650-200502000-00012","article-title":"Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research","volume":"43","author":"Lee","year":"2005","journal-title":"Med Care"},{"key":"10.1136\/annrheumdis-2012-202136_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jama.292.3.344","article-title":"Trends in heart failure incidence and survival in a community-based population","volume":"292","author":"Roger","year":"2004","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2012-202136_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1136\/annrheumdis-2012-202136_bib19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1524-4733.2009.00602.x","volume":"12","author":"Johnson","year":"2009","journal-title":"Value Health"},{"key":"10.1136\/annrheumdis-2012-202136_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of Martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1136\/annrheumdis-2012-202136_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1136\/annrheumdis-2012-202136_bib22","first-page":"764","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.(summary for patients in Ann Intern Med. 2004 Nov 16;141(10):I58; PMID: 15545672)","volume":"141","author":"Wei","year":"2004"},{"key":"10.1136\/annrheumdis-2012-202136_bib23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1136\/annrheumdis-2012-202136_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","article-title":"Developments in post-marketing comparative effectiveness research","volume":"82","author":"Schneeweiss","year":"2007","journal-title":"Clin Pharm Ther"},{"key":"10.1136\/annrheumdis-2012-202136_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.20855","article-title":"The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years","volume":"52","author":"Nicola","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202136_bib26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/art.23798","article-title":"The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population","volume":"58","author":"Davis","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202136_bib27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/ard.2009.124362","article-title":"Increased prevalence of diastolic dysfunction in rheumatoid arthritis","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202136_bib28","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"key":"10.1136\/annrheumdis-2012-202136_bib29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724213157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724213157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2012-202136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:44:16Z","timestamp":1737351856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724213157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0003496724213157"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202136","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}